Investing.com -- Shares of Eli Lilly and Company (NYSE: LLY) climbed as much as 2.6% before settling up 0.5% after the pharmaceutical giant reported highly positive Phase 2b trial results for its new obesity and type 2 diabetes drug combination. As Lilly's stock advanced, shares of primary competitor Novo Nordisk slipped 0.3% on the news. Before you buy NVIDIA: our AI model's stock picks are beating the market by 120%+. See the list now » The experimental therapy, EloraTZP—a combination of eloralintide and tirzepatide—delivered headline-grabbing weight loss that significantly outpaced current treatments. In a 48-week trial of 367 participants, the combination drove an average weight loss of up to 54.1 lbs (23.3%), drastically outperforming the 34.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.